News from the global pharmaceuticals industry about head lice treatments and corporate developments, including takeovers and mergers.
Eden Research has announced an agreement with Neo-Pharma Innovations to develop their terpene-based head lice treatment for commercial sale.
Hatchtech, Pty Ltd have announced the completion of their financing round and published new data on the active ingredient in their DeOvo pediculicide product.
TyraTech, Inc, has received notification from the UK regualtory body that their VaMOUSSE!™ head lice product has been registered as a medical device.
The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.
Sanofi Pasteur announced this week that Sklice, their ivermectin-based head lice treatment is now commercially available by prescription in the US.
The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.
An agreement dated 19 March 2012 has been made between Eden Research plc, an agrochemical and encapsulation technology company, and Phytalexin Ltd. This grants Phytalexin exclusive rights to Eden's formulations and encapsulation technologies for use in a head-lice product.